Skip to main content
. 2016 Aug 17;16:644. doi: 10.1186/s12885-016-2709-z

Fig. 2.

Fig. 2

Flowcharts summarizing the 3 + 3 dose escalating study design. In the first cohort of patients evofosfamide will be administered at a dose of 120 mg/m2. Depending on the observed toxicity, we will escalate to dose level 2, or de-escalate to dose level -1. In further dose levels we can only escalate to the next dose (up to 340 mg/m2) or stop due to dose limiting toxicity